| Covariate . | Univariable analysis . | Multivariable analysis . | |||
|---|---|---|---|---|---|
| HR (95%CI) . | P-value . | n . | HR (95%CI) . | P-value . | |
| Age1 | 0.98 (0.96-1.00) | .016 | 115 | 0.98 (0.96-1.00) | .098 |
| Male sex | 0.62 (0.39-0.99) | .044 | 115 | 0.65 (0.37-1.15) | .14 |
| CCI | 0.84 (0.63-1.10) | .20 | 115 | 0.87 (0.66-1.16) | .34 |
| ECOG1 | 50 | ||||
| 0-1 | Reference | — | 35 | — | — |
| 2-3 | 1.98 (1.05-3.74) | .035 | 15 | — | — |
| Location of primary tumour | .31 | 115 | |||
| GEJ (Siewart I-III) | Reference | — | 55 | Reference | — |
| Esophagus | 0.81 (0.41-1.6) | .54 | 11 | 0.83 (0.41-1.67) | .60 |
| Gastric | 1.30 (0.84-2.03) | .24 | 49 | 1.16 (0.69-1.97) | .59 |
| Tumour grade | .034 | 115 | — | — | |
| G1 | Reference | — | 8 | — | — |
| G2 | 1.73 (0.62-4.28) | .32 | 28 | — | — |
| G3 | 2.91 (1.14-7.47) | .03 | 49 | — | — |
| HER2 status | 0.78 (0.49-1.23) | .29 | 115 | 0.69 (0.43-1.11) | .13 |
| Covariate . | Univariable analysis . | Multivariable analysis . | |||
|---|---|---|---|---|---|
| HR (95%CI) . | P-value . | n . | HR (95%CI) . | P-value . | |
| Age1 | 0.98 (0.96-1.00) | .016 | 115 | 0.98 (0.96-1.00) | .098 |
| Male sex | 0.62 (0.39-0.99) | .044 | 115 | 0.65 (0.37-1.15) | .14 |
| CCI | 0.84 (0.63-1.10) | .20 | 115 | 0.87 (0.66-1.16) | .34 |
| ECOG1 | 50 | ||||
| 0-1 | Reference | — | 35 | — | — |
| 2-3 | 1.98 (1.05-3.74) | .035 | 15 | — | — |
| Location of primary tumour | .31 | 115 | |||
| GEJ (Siewart I-III) | Reference | — | 55 | Reference | — |
| Esophagus | 0.81 (0.41-1.6) | .54 | 11 | 0.83 (0.41-1.67) | .60 |
| Gastric | 1.30 (0.84-2.03) | .24 | 49 | 1.16 (0.69-1.97) | .59 |
| Tumour grade | .034 | 115 | — | — | |
| G1 | Reference | — | 8 | — | — |
| G2 | 1.73 (0.62-4.28) | .32 | 28 | — | — |
| G3 | 2.91 (1.14-7.47) | .03 | 49 | — | — |
| HER2 status | 0.78 (0.49-1.23) | .29 | 115 | 0.69 (0.43-1.11) | .13 |
PFS is defined as start of ram/pac to time of disease progression or last dose of ram/pac.
1At the time of starting rampac.
| Covariate . | Univariable analysis . | Multivariable analysis . | |||
|---|---|---|---|---|---|
| HR (95%CI) . | P-value . | n . | HR (95%CI) . | P-value . | |
| Age1 | 0.98 (0.96-1.00) | .016 | 115 | 0.98 (0.96-1.00) | .098 |
| Male sex | 0.62 (0.39-0.99) | .044 | 115 | 0.65 (0.37-1.15) | .14 |
| CCI | 0.84 (0.63-1.10) | .20 | 115 | 0.87 (0.66-1.16) | .34 |
| ECOG1 | 50 | ||||
| 0-1 | Reference | — | 35 | — | — |
| 2-3 | 1.98 (1.05-3.74) | .035 | 15 | — | — |
| Location of primary tumour | .31 | 115 | |||
| GEJ (Siewart I-III) | Reference | — | 55 | Reference | — |
| Esophagus | 0.81 (0.41-1.6) | .54 | 11 | 0.83 (0.41-1.67) | .60 |
| Gastric | 1.30 (0.84-2.03) | .24 | 49 | 1.16 (0.69-1.97) | .59 |
| Tumour grade | .034 | 115 | — | — | |
| G1 | Reference | — | 8 | — | — |
| G2 | 1.73 (0.62-4.28) | .32 | 28 | — | — |
| G3 | 2.91 (1.14-7.47) | .03 | 49 | — | — |
| HER2 status | 0.78 (0.49-1.23) | .29 | 115 | 0.69 (0.43-1.11) | .13 |
| Covariate . | Univariable analysis . | Multivariable analysis . | |||
|---|---|---|---|---|---|
| HR (95%CI) . | P-value . | n . | HR (95%CI) . | P-value . | |
| Age1 | 0.98 (0.96-1.00) | .016 | 115 | 0.98 (0.96-1.00) | .098 |
| Male sex | 0.62 (0.39-0.99) | .044 | 115 | 0.65 (0.37-1.15) | .14 |
| CCI | 0.84 (0.63-1.10) | .20 | 115 | 0.87 (0.66-1.16) | .34 |
| ECOG1 | 50 | ||||
| 0-1 | Reference | — | 35 | — | — |
| 2-3 | 1.98 (1.05-3.74) | .035 | 15 | — | — |
| Location of primary tumour | .31 | 115 | |||
| GEJ (Siewart I-III) | Reference | — | 55 | Reference | — |
| Esophagus | 0.81 (0.41-1.6) | .54 | 11 | 0.83 (0.41-1.67) | .60 |
| Gastric | 1.30 (0.84-2.03) | .24 | 49 | 1.16 (0.69-1.97) | .59 |
| Tumour grade | .034 | 115 | — | — | |
| G1 | Reference | — | 8 | — | — |
| G2 | 1.73 (0.62-4.28) | .32 | 28 | — | — |
| G3 | 2.91 (1.14-7.47) | .03 | 49 | — | — |
| HER2 status | 0.78 (0.49-1.23) | .29 | 115 | 0.69 (0.43-1.11) | .13 |
PFS is defined as start of ram/pac to time of disease progression or last dose of ram/pac.
1At the time of starting rampac.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
